deCODE Receives California Clinical Laboratory License
News Feb 24, 2009
deCODE genetics has announced that it has received a clinical laboratory license from the State of California. The quality and scale of deCODE’s in-house, CLIA-registered genotyping laboratory underpins deCODE’s global leadership in the discovery of variations in the sequence of the human genome conferring risk of common diseases.
The same staff and facility also process deCODE’s DNA-based reference laboratory tests for gauging individual risk of major public health challenges ranging from heart attack to breast cancer, as well as the company’s deCODEme™ scans. The company says that with this license, California residents can now benefit from the unrivalled quality of deCODE products for understanding risk and, working with their physicians, empowering the prevention of common diseases.
Through its reference laboratory testing service, www.decodediagnostics.com, deCODE offers DNA-based tests for assessing individual risk of heart attack, type 2 diabetes, stroke, breast cancer, prostate cancer, and glaucoma.
deCODEme™ is said to be the world’s first retail genome analysis service, available at www.decodeme.com. The full genome Complete Scan scan and the Cardio and Cancer scans build on deCODE’s discovery of common variations in the sequence of the human genome conferring increased risk of common diseases.
GM Mice Bear Many of the Hallmarks of Human Bipolar BehaviourNews
Study shows that the behaviour responds to lithium treatment, just as used in people with the disorder.READ MORE
Ancient Genes Take on New Functions as Master RegulatorsNews
Researchers find that about 60 lncRNA genes in mammals – or 2% to 3% of lncRNAs shared by humans and other mammalian species – appear to be derived from ancestral, protein-coding genes.READ MORE
Metabolic Classification of Human Hepatoblastoma UncoveredNews
EPFL scientists have now found metabolic differences between hepatoblastoma subtypes, and identified several biomarkers that can help obtain more accurate subtyping of the disease.READ MORE